# Sacheerome share price today (Sacheerome Ltd, NSE: SACHEEROME) > Sacheerome share price today: ₹378.30 at the NSE close on 20 November 2026, up 6.1% in a year. Sacheerome (NSE: SACHEEROME) is worth ₹846 crore, trades at a P/E of 27.9 and has closed between ₹260.30 and ₹536.85 over the past 52 weeks. > Sacheerome Ltd's earnings have grown faster than its share price. Earnings per share grew +30.0% in a year while the price moved +6.1%. SACHEEROME · Chemicals - Organic · data as of 20 November 2026. Page: https://www.sectoralpha.in/stocks/sacheerome-ltd Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms ## Key numbers - Price: ₹378.30 (+6.1% in a year) - P/E: 27.9× (lower than 57% of the last 1 year) - Revenue (Sep 2026): ₹84.0 Cr (+9.1% on a year ago) - Profit (Sep 2026): ₹17.0 Cr (+13.3% on a year ago) - Operating margin: 26.2% (+1.5 points on a year ago) - ROCE: 36%, FY26 Biggest thing to watch: margins are the best this company has ever reported. Every ratio looks better at a record, so the story depends on margins staying high. ## What is the Sacheerome share price today? Sacheerome Ltd's share price was ₹378.30 at the close on 20 November 2026. It is in an uptrend that has just slipped below its 200-day average. That is 4.2% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹260 and ₹537, and at that close it sat 43% of the way up from that low. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 5 weeks running. Over the last 1 year the share price moved +143% while the NIFTY 500 moved +3%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 23 October 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Sacheerome this quarter? Three changes stood out: indian funds and insurers (DIIs) cut their stake for 3 quarters in a row, foreign funds (FIIs) cut their stake for 3 quarters in a row and number of shareholders up 67% in a year. 1. Indian funds and insurers (DIIs) cut their stake for 3 quarters in a row From 12.8% to 5.1% of the company by the September 2026 quarter. 2. Foreign funds (FIIs) cut their stake for 3 quarters in a row From 1.5% to 0.1% of the company by the September 2026 quarter. 3. Number of shareholders up 67% in a year 1,905 shareholders in the September 2026 quarter, against 1,141 a year earlier. ## What are Sacheerome's latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), Sacheerome reported revenue of ₹84.0 crore, up 9.1% from ₹77.0 crore a year earlier, and a profit of ₹17.0 crore, up 13.3% from ₹15.0 crore. ### Sacheerome results: July to September 2026 against a year earlier | Measure | July to September 2026 | July to September 2025 | Change | | --- | --- | --- | --- | | Revenue | ₹84.0 crore | ₹77.0 crore | +9.1% | | Profit | ₹17.0 crore | ₹15.0 crore | +13.3% | | Earnings per share | ₹7.50 | ₹6.68 | +12.3% | | Operating margin | 26.2% | 24.7% | +1.5 points | The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Sacheerome's management discussed these results on a call held on 4 November 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.) ## What is the Sacheerome share price history? Sacheerome closed at ₹378.30 on 20 November 2026, up 6.1% from ₹356.55 a year earlier (21 November 2025). Its highest weekly close since June 2025 was ₹536.85 on 18 September 2026. ### Sacheerome share price: then and now | When | Close | Change to 20 Nov 2026 | | --- | --- | --- | | 1 week ago · 13 Nov 2026 | ₹369.55 | +2.4% | | 1 month ago · 19 Oct 2026 | ₹459.50 | −17.7% | | 6 months ago · 22 May 2026 | ₹335.05 | +12.9% | | 1 year ago · 21 Nov 2025 | ₹356.55 | +6.1% | | Earliest and lowest weekly close in our records · 20 Jun 2025 | ₹155.45 | +143.4% | | Highest weekly close since June 2025, also the 52-week high · 18 Sep 2026 | ₹536.85 | −29.5% | | 52-week low (weekly close) · 25 Mar 2026 | ₹260.30 | +45.3% | Weekly closing prices. Each change is the move from that price to the 20 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (80 weekly closes from 20 June 2025 to 20 November 2026.) ## What is the latest news on Sacheerome? 20 Nov 2026: Sacheerome closed at ₹378.30, up 2.4% on the week and down 17.7% on the month. 4 Nov 2026: Sacheerome held its results call for July to September 2026. Management guided: Combined ₹300 crore FY29 revenue to be met and termed conservative. ### Earlier - Results for July to September 2026: Revenue up 9.1% and profit up 13.3% on a year earlier. ## What dividend does Sacheerome pay? Sacheerome has paid no dividend on the NSE since its first NSE close in our records (20 June 2025), the start of the period we checked. No. Sacheerome Ltd paid out 0% of its profit as dividends in each of its last 5 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate. (From the NSE corporate-actions record, read 20 November 2026.) ## What did Sacheerome management say on the latest results call? On the call for July to September 2026, held on 4 November 2026, Sacheerome's management guided: Combined ₹300 crore FY29 revenue to be met and termed conservative. > “I do not see any reason why we would not maintain our profit margin and EBITDA. We do not see any challenge.” > Manoj Arora, on the call for July to September 2026 ### What management guided - YEIDA asset turnover around 1x as utilization builds. - Profit and operating margin to be maintained through ramp with no challenge seen. - YEIDA ramp-up to proceed very quickly on customer pressure with quick execution. - Final certificates receipt at YEIDA near term followed by progressive production scale-up. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijoristack.ai/concall/transcript/58639-04-Nov-2026.pdf). (From the call for July to September 2026, 4 November 2026.) ## What to watch in Sacheerome's next results? When Sacheerome reports October to December 2026, these are the 3 checks that show whether the story is still on course. First: YEIDA final certificates receipt and first commercial supplies - check issuance and scale-up start. Management raised each of these on the latest results call. - YEIDA final certificates receipt and first commercial supplies - check issuance and scale-up start. - YEIDA utilization ramp pace under customer pressure - check progress toward full use and margin continuity. - Second-half sales acceleration on customer launches and YEIDA supplies - check growth uptick versus half-year pace. ## Which stock lists is Sacheerome on? Sacheerome is not on any of our India lists this week. ## Is Sacheerome profitable? Sacheerome Ltd earned ₹17.0 Cr of net profit in the Sep 2026 quarter, +13.3% on the same quarter a year earlier. That is the 3rd quarter in a row of profit growth. Full-year FY26 profit was ₹28.0 Cr. Over 4 years profit has grown 53.8% a year on average. The Sep 2026 quarter's profit is 20.2% of that quarter's revenue. The same quarter a year earlier earned ₹7.0 Cr. For the full year, FY26 profit was ₹28.0 Cr (+75.0% on the year before). Why profit moved: revenue changed +9.1% on a year earlier and the margin moved +1.5 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed +61.1% and revenue +32.1%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does Sacheerome make, and is it growing? Sacheerome Ltd reported ₹84.0 Cr of revenue in the Sep 2026 quarter, +9.1% on the same quarter a year earlier. That is the 3rd quarter in a row with growth on the year before. Over 4 years it has grown 24.1% a year on average. The last full year, FY26, came in at ₹152 Cr. FY26 revenue was ₹152 Cr, +40.7% on the year before. Recent pace: the last four quarters grew +32.1% on average, against 24.1% a year over the longer run, so this year is growing faster than its own long-run rate. ## How much of every ₹100 of sales does Sacheerome keep? Sacheerome Ltd's operating margin was 26.2% in the Sep 2026 quarter, 1.5 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Over the last four quarters it has moved +6.2 percentage points. Across 5 years it has been between 14.1% and 24.3%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +7.0 percentage points on the year while gross margin changed +0.5 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. As noted under valuation: when margins are at a record, every ratio built on profit looks better than usual, so a low multiple can mislead. ## Is Sacheerome's profit turning into cash? Over the last 3 years, 105% of Sacheerome Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹26.0 Cr of operating cash against ₹28.0 Cr of profit. After ₹40.0 Cr of spending on assets, free cash was −₹14.0 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 105% of profit came in as cash: the cash cycle got 76 days shorter between FY22 and FY26, so cash that used to wait in the business now arrives sooner. What to look at next: the bigger use of cash is spending on new assets, at 12.3× depreciation over three years. The next section checks what that spending is building. ## Where does Sacheerome's cash go? Sacheerome Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 33 days in FY26, down from 109 days in FY22. It spent ₹74.0 Cr on assets over the last 3 years. Customers take 47 days to pay, and stock sits for 47 days on average. At FY26 sales of ₹152 Cr, each day of that cycle ties up about ₹0.4 Cr, so roughly ₹14.0 Cr is tied up in the business at any time. FY26: customers took 47 days to pay and stock sat for 47 days, about 1.5 months of sales sitting as stock, for a full cycle of 33 days, shorter than FY22's 109. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 47 days. Customers pay about 47 days after that. Suppliers are paid at 61 days. Together that makes the 33-day cycle. Spending on assets: ₹74.0 Cr over the last 3 years, against ₹6.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹57.0 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Sacheerome's P/E ratio, and how does it compare with its own history? Sacheerome Ltd's P/E is 27.9×, in the middle of its own history: higher than 43% of past readings. Its usual P/E (the middle reading) is 28.8×, over 1 year of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Keep one thing in mind: margins are the best this company has ever reported. A multiple that looks low against its own past can mislead when profit is at a record. If margins fall back, today's multiple is higher than it looks. Why the multiple is where it is: over the past year earnings per share moved +30.0% while the price moved +6.1%. Earnings did better than the price, which pulled the multiple down within its own range. In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple. A quarterly PEG curve, which only the second data source has, is not shown on this page: its two data sources disagree by up to 49% on reported income across 4 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Is the Sacheerome business getting better or worse? Sacheerome Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 4 quarters of 1 measure, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Sacheerome earn on its capital? Sacheerome Ltd earned a ROCE of 36% in FY26. That is up from a low of 24% in FY23. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a 18.4% net margin and 0.88× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 18.4% net margin × 0.88× asset turnover × 1.16× leverage (assets divided by equity) ≈ 18.8% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. The quarterly return lines and the return-on-capital-used (ROIC) line, which only the second data source has, are not shown on this page: its two data sources disagree by up to 49% on reported income across 4 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Does Sacheerome have too much debt? Sacheerome Ltd had ₹0.0 Cr of borrowings against ₹148 Cr of equity in FY26, so its debt is 0.00× its equity. Over 4 years borrowings went from ₹8.0 Cr to ₹0.0 Cr. Over the last 3 of those years it spent ₹74.0 Cr on assets. The spending on assets is being paid for from cash, not new debt. ## What is the Sacheerome shareholding pattern? No group of Sacheerome Ltd's owners changed its stake by a full percentage point over the last 4 quarters. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. ## How far is Sacheerome from balance-sheet trouble? For Sacheerome Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Sacheerome rank in its industry? 55.6 out of 100, rank 19 of 20 in Chemicals - Organic, with 36% of the evidence available. It is provisional, so it is ranked below companies with full evidence. Sacheerome Ltd scores 55.6 out of 100 against the 20 companies it is compared with in Chemicals - Organic, ranking 19. Some evidence is missing, so the score is pulled toward the middle on purpose. The four parts add up to the total exactly: 17.2 + 20.6 + 9.9 + 7.9 = 55.6. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Sacheerome compared with? Sacheerome ranks 19 of 20 Chemicals - Organic companies on the 4-Factor Sector Score, with 55.6 out of 100. 1. [Nitta Gelatin India Ltd](https://www.sectoralpha.in/stocks/nitta-gelatin-india-ltd) NITTAGELA · turning · Most evidence points up · 75% evidence 71.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.9/35 · Revenue 15% · Profit 49.4% · Operating margin change 9 points · 100% evidence Capital efficiency 21.2/25 · ROCE 27.7% (year to Mar 2026) · Operating margin 28.4% · 100% evidence Valuation 9.8/20 · P/E 12.6× · PEG n/a · 50% evidence Relative strength 12.5/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 31.1% · 1 year n/a · 25% evidence · 4 of 12 weeks ahead Exact sum: 27.9 + 21.2 + 9.8 + 12.5 = 71.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Laxmi Organic Industries Ltd](https://www.sectoralpha.in/stocks/laxmi-organic-industries-ltd) LXCHEM · quiet · Most evidence points up · 85% evidence 69.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.9/35 · Revenue 21.3% · Profit 100% · Operating margin change 5 points · 100% evidence Capital efficiency 10.7/25 · ROCE 4.7% (year to Mar 2026) · Operating margin 10% · 100% evidence Valuation 18.6/20 · P/E 24.4× · PEG 0.64 · 100% evidence Relative strength 8.9/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) -2.3% · 1 year -17.4% · 25% evidence · 7 of 12 weeks ahead Exact sum: 30.9 + 10.7 + 18.6 + 8.9 = 69.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Valiant Organics Ltd](https://www.sectoralpha.in/stocks/valiant-organics-ltd) VALIANTORG · breaking out · Evidence leans up · 82% evidence 61.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.4/35 · Revenue 21.4% · Profit 100% · Operating margin change 0 points · 95% evidence Capital efficiency 8.2/25 · ROCE 5.5% (year to Mar 2026) · Operating margin 12.8% · 76% evidence Valuation 11.9/20 · P/E 13.8× · PEG n/a · 50% evidence Relative strength 17.0/20 · Strength vs its industry (price vs its 52-week average, weekly) 11.6% · Strength vs NIFTY 500 (same reading) 17.1% · 1 year 20.3% · 100% evidence · 11 of 12 weeks ahead Exact sum: 24.4 + 8.2 + 11.9 + 17 = 61.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [OCCL Ltd](https://www.sectoralpha.in/stocks/occl-ltd) OCCLLTD · losing its lead · Evidence leans up · 60% evidence 58.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.6/35 · Revenue 65.9% · Profit 100% · Operating margin change 3 points · 95% evidence Capital efficiency 11.6/25 · ROCE 13% (year to Mar 2026) · Operating margin 18.7% · 76% evidence Valuation 11.5/20 · P/E 7.9× · PEG n/a · 15% evidence Relative strength 12.1/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 20% · 1 year n/a · 25% evidence · 11 of 12 weeks ahead Exact sum: 23.6 + 11.6 + 11.5 + 12.1 = 58.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Balaji Amines Ltd](https://www.sectoralpha.in/stocks/balaji-amines-ltd) BALAMINES · quiet · Evidence leans up · 82% evidence 58.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.3/35 · Revenue 20.9% · Profit 66.2% · Operating margin change 4 points · 95% evidence Capital efficiency 13.0/25 · ROCE 11% (year to Mar 2026) · Operating margin 21.8% · 76% evidence Valuation 9.5/20 · P/E 24.9× · PEG n/a · 50% evidence Relative strength 10.8/20 · Strength vs its industry (price vs its 52-week average, weekly) 8.7% · Strength vs NIFTY 500 (same reading) 13.7% · 1 year 54.4% · 100% evidence · 4 of 12 weeks ahead Exact sum: 25.3 + 13 + 9.5 + 10.8 = 58.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Shri Ahimsa Naturals Ltd](https://www.sectoralpha.in/stocks/shri-ahimsa-naturals-ltd) SHRIAHIMSA · losing its lead · Too little evidence to rank firmly · 58% evidence 58.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 16.0/35 · Revenue n/a · Profit n/a · Operating margin change -2 points · 27% evidence Capital efficiency 18.7/25 · ROCE 21.7% (year to Mar 2026) · Operating margin 27.5% · 100% evidence Valuation 9.7/20 · P/E 29.6× · PEG n/a · 15% evidence Relative strength 14.1/20 · Strength vs its industry (price vs its 52-week average, weekly) 13.8% · Strength vs NIFTY 500 (same reading) 19.1% · 1 year 44.8% · 100% evidence · 8 of 12 weeks ahead Exact sum: 16 + 18.7 + 9.7 + 14.1 = 58.5 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 7. [Elantas Beck India Ltd](https://www.sectoralpha.in/stocks/elantas-beck-india-ltd) ELANTAS · losing its lead · Evidence leans up · 67% evidence 56.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.6/35 · Revenue 18.7% · Profit 35.5% · Operating margin change 1 points · 95% evidence Capital efficiency 18.6/25 · ROCE 21.2% (year to Dec 2025) · Operating margin 23% · 76% evidence Valuation 7.1/20 · P/E 51.1× · PEG n/a · 50% evidence Relative strength 11.6/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 16.7% · 1 year 29.3% · 25% evidence · 10 of 12 weeks ahead Exact sum: 19.6 + 18.6 + 7.1 + 11.6 = 56.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [BASF India Ltd](https://www.sectoralpha.in/stocks/basf-india-ltd) BASF · quiet · Evidence leans up · 75% evidence 54.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.0/35 · Revenue 15.4% · Profit 59.5% · Operating margin change -2.1 points · 100% evidence Capital efficiency 10.8/25 · ROCE 14.5% (year to Mar 2026) · Operating margin 1.9% · 100% evidence Valuation 13.7/20 · P/E 21.1× · PEG n/a · 50% evidence Relative strength 7.5/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) -21.8% · 1 year -33.9% · 25% evidence · 3 of 12 weeks ahead Exact sum: 22 + 10.8 + 13.7 + 7.5 = 54 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Fine Organic Industries Ltd](https://www.sectoralpha.in/stocks/fine-organic-industries-ltd) FINEORG · losing its lead · Evidence leans up · 100% evidence 53.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.2/35 · Revenue 12.7% · Profit 18.5% · Operating margin change 3 points · 100% evidence Capital efficiency 18.0/25 · ROCE 21.5% (year to Mar 2026) · Operating margin 25% · 100% evidence Valuation 6.7/20 · P/E 34.9× · PEG 2.54 · 100% evidence Relative strength 10.1/20 · Strength vs its industry (price vs its 52-week average, weekly) 1.5% · Strength vs NIFTY 500 (same reading) 7.9% · 1 year 20.9% · 100% evidence · 6 of 12 weeks ahead Exact sum: 18.2 + 18 + 6.7 + 10.1 = 53 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 10. [Indo Amines Ltd](https://www.sectoralpha.in/stocks/indo-amines-ltd) INDOAMIN · quiet · Evidence leans up · 75% evidence 52.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 16.2/35 · Revenue 22.2% · Profit 2.3% · Operating margin change -6.1 points · 100% evidence Capital efficiency 14.9/25 · ROCE 18.9% (year to Mar 2026) · Operating margin 5.5% · 100% evidence Valuation 13.5/20 · P/E 11.3× · PEG n/a · 50% evidence Relative strength 8.0/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) -7.7% · 1 year -11.1% · 25% evidence · 3 of 12 weeks ahead Exact sum: 16.2 + 14.9 + 13.5 + 8 = 52.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Fairchem Organics Ltd](https://www.sectoralpha.in/stocks/fairchem-organics-ltd) FAIRCHEMOR · losing its lead · Evidence leans up · 90% evidence 50.8 out of 100 Growth Capital Valuation Relative 12. [Jyoti Resins and Adhesives Ltd](https://www.sectoralpha.in/stocks/jyoti-resins-and-adhesives-ltd) JYOTIRES · turning · Evidence leans down · 68% evidence 49.6 out of 100 Growth Capital Valuation Relative 13. [Foseco India Ltd](https://www.sectoralpha.in/stocks/foseco-india-ltd) FOSECOIND · leader · Evidence leans down · 67% evidence 46.1 out of 100 Growth Capital Valuation Relative 14. [GFL Ltd](https://www.sectoralpha.in/stocks/gfl-ltd) GFLLIMITED · breaking out · Evidence leans down · 83% evidence 44.9 out of 100 Growth Capital Valuation Relative 15. [Oriental Aromatics Ltd](https://www.sectoralpha.in/stocks/oriental-aromatics-ltd) OAL · leader · Evidence leans down · 68% evidence 44.6 out of 100 Growth Capital Valuation Relative 16. [Sigachi Industries Ltd](https://www.sectoralpha.in/stocks/sigachi-industries-ltd) SIGACHI · losing its lead · Evidence leans down · 90% evidence 43.2 out of 100 Growth Capital Valuation Relative 17. [Shree Ganesh Remedies Ltd](https://www.sectoralpha.in/stocks/shree-ganesh-remedies-ltd) SGRL · breaking out · Evidence leans down · 75% evidence 36.4 out of 100 Growth Capital Valuation Relative 18. [Gem Aromatics Ltd](https://www.sectoralpha.in/stocks/gem-aromatics-ltd) GEMAROMA · basing · Too little evidence to rank firmly · 51% evidence 34.2 out of 100 Growth Capital Valuation Relative 19. Sacheerome Ltd this page SACHEEROME · losing its lead · Too little evidence to rank firmly · 36% evidence 55.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.2/35 · Revenue n/a · Profit n/a · Operating margin change 1 points · 26% evidence Capital efficiency 20.6/25 · ROCE 35.7% (year to Mar 2026) · Operating margin 26.2% · 76% evidence Valuation 9.9/20 · P/E 27.9× · PEG n/a · 15% evidence Relative strength 7.9/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) -8.6% · 1 year 6.1% · 25% evidence · 8 of 12 weeks ahead Exact sum: 17.2 + 20.6 + 9.9 + 7.9 = 55.6 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 20. [Citurgia Biochemicals Ltd](https://www.sectoralpha.in/stocks/citurgia-biochemicals-ltd) CITURGIA · quiet · Too little evidence to rank firmly · 25% evidence 34.3 out of 100 Growth Capital Valuation Relative Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. In this ranking every company's P/E uses its own latest official close and its last four filed quarters, the same rule as the top of this page. ROCE here is each company's last full year, as labelled, so it can differ from the four-quarter ROCE above. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Chemicals - Organic](https://www.sectoralpha.in/sectors/chemicals-organic), all 20 compared on one page. ## Which companies are close to Sacheerome in size? Sacheerome is the 14th largest of 20 Chemicals - Organic companies on Sector Alpha by market value (at the 20 November 2026 close). Just above it: Jyoti Resins and Adhesives, Valiant Organics and Shri Ahimsa Naturals. Just below it: Fairchem Organics, Indo Amines and Shree Ganesh Remedies. ### Chemicals - Organic companies close in size 1. [Jyoti Resins and Adhesives Ltd](https://www.sectoralpha.in/stocks/jyoti-resins-and-adhesives-ltd) ₹1,156 crore 2. [Valiant Organics Ltd](https://www.sectoralpha.in/stocks/valiant-organics-ltd) ₹906 crore 3. [Shri Ahimsa Naturals Ltd](https://www.sectoralpha.in/stocks/shri-ahimsa-naturals-ltd) ₹900 crore 4. Sacheerome Ltd ₹847 crore 5. [Fairchem Organics Ltd](https://www.sectoralpha.in/stocks/fairchem-organics-ltd) ₹825 crore 6. [Indo Amines Ltd](https://www.sectoralpha.in/stocks/indo-amines-ltd) ₹813 crore 7. [Shree Ganesh Remedies Ltd](https://www.sectoralpha.in/stocks/shree-ganesh-remedies-ltd) ₹778 crore [All 20 Chemicals - Organic companies, largest first](https://www.sectoralpha.in/sectors/chemicals-organic#all-companies) ### Companies close in size in other industries 1. [Gayatri Projects Ltd](https://www.sectoralpha.in/stocks/gayatri-projects-ltd) ₹849 crore · Construction - Civil/Turnkey 2. [Sudarshan Colorants India Ltd](https://www.sectoralpha.in/stocks/sudarshan-colorants-india-ltd) ₹848 crore · Dyes & Pigments 3. Sacheerome Ltd ₹847 crore 4. [Unified Data- Tech Solutions Ltd](https://www.sectoralpha.in/stocks/unified-data-tech-solutions-ltd) ₹846 crore · IT - Software 5. [Hexa Tradex Ltd](https://www.sectoralpha.in/stocks/hexa-tradex-ltd) ₹845 crore · Trading ## What else do people ask about Sacheerome? ### What were Sacheerome's latest quarterly results? Sacheerome Ltd reported revenue of ₹84.0 Cr and net profit of ₹17.0 Cr for the Sep 2026 quarter. Revenue rose 9.1% and profit rose 13.3% compared with a year earlier. Earnings per share were ₹7.50. The operating margin was 26.2%, 1.5 percentage points higher than a year earlier (as of 20 November 2026). ### What is Sacheerome's market cap? Sacheerome Ltd's market capitalisation is ₹846 Cr at a share price of ₹378.30. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 20 November 2026). ### How is Sacheerome performing? Sacheerome Ltd's share price is in an uptrend that has just slipped below its 200-day average. In its latest quarter, revenue rose 9.1% and profit rose 13.3% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 5 weeks running (as of 20 November 2026). ### Is Sacheerome in an uptrend? Yes, the price has been rising for 70 weeks (stage 2 of 4), 4.2% below its 200-day average, and 43% of the way up its 52-week range. A share price tends to move through four phases: moving sideways, rising, stalling and falling (as of 20 November 2026). ### Will Sacheerome's share price go up? This page does not forecast Sacheerome Ltd's share price. What it shows instead: the share price is ₹378.30, and it has been rising for 70 weeks. Its P/E of 27.9× is higher than 43% of its own last 1 years (as of 20 November 2026). ### Who owns Sacheerome? Promoters own 71.5% of Sacheerome Ltd, foreign institutions 0.1%, domestic institutions 5.1% and the public 23.3% (latest quarter). No group of owners changed its stake by a full point over the last two years (as of 20 November 2026). ### Where is Sacheerome in its business cycle? Sacheerome Ltd's FY26 operating margin was 24.3%, against a 5-year range of 14.1% to 24.3%. The latest quarter was 26.2%, above the top of its own yearly range in the latest quarter, so margins are at a high and the story depends on them staying there. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 20 November 2026). ### What could break the Sacheerome story? Biggest thing to watch: margins are the best this company has ever reported. Every ratio looks better at a record, so the story depends on margins staying high. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 20 November 2026). ### Is Sacheerome a stock worth studying right now? What the numbers show: Sacheerome Ltd's earnings have grown faster than its share price. Earnings per share grew +30.0% in a year while the price moved +6.1%. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 20 November 2026). ### Is there a Sacheerome share price forecast for 2026? What management itself guided: Combined ₹300 crore FY29 revenue to be met and termed conservative. This is research, not advice. We’re not SEBI-registered.